EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access

Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study

Sairah Ahmed, Qaiser Bashir iD, Roland L Bassett, Fauzia Ullah, Fleur Aung, Benigno C Valdez, Amin M Alousi, Chitra Hosing, Partow Kebriaei, Issa Khouri iD, David Marin, Yago Nieto iD und 10 weitere

American Journal of Hematology · 2024

DOI: 10.1002/ajh.27233 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift American Journal of Hematology, 2024. Verfasst von Sairah Ahmed und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, Benzoates, Hydrazines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, GlaxoSmithKline, Novartis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Slow platelet recovery frequently occurs after haploidentical hematopoietic stem cell transplantation (haplo‐HSCT) with bone marrow graft and post‐transplant cyclophosphamide (PCy)‐based graft‐versus‐host disease (GVHD) prophylaxis. Improved platelet recovery may reduce the need for transfusions and improve outcomes. We investigated the safety and efficacy of eltrombopag, a thrombopoietin receptor agonist, at enhancing platelet recovery post‐haplo‐HSCT. The prospective study included patients ≥18 years of age who received haplo‐HSCT with bone marrow graft and PCy. Patients received eltrombopag 300 mg/day starting on Day +5. The primary objective was to estimate platelet engraftment (>50 000/μL by Day 60). In a post hoc analysis, they were compared to a contemporary matched control group who did not receive eltrombopag. One hundred ten patients were included in the analysis (30 eltrombopag and 80 control). Seventy‐three percent and 50% of patients in the eltrombopag group and control group, respectively, attained >50 000/μL platelet count by Day 60 ( p = .043). No eltrombopag‐related grade ≥4 adverse events were observed. Median time to platelet recovery (>20 000/μL) was 29 days with eltrombopag and 31 days for controls ( p = .022), while its cumulative incidence was 90% (95% confidence interval [CI]: 78%–100%) with eltrombopag versus 67.5% (95% CI: 57%–78%) for controls ( p = .014). Number of platelet transfusions received, overall survival, progression‐free survival, GVHD rate, relapse rate, and non‐relapse mortality were similar between groups. Overall, eltrombopag is safe and improves platelet recovery in patients undergoing haplo‐HSCT with bone marrow graft and PCy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationGraft vs Host DiseaseBenzoatesHydrazinesPyrazolesHumansBone Marrow TransplantationProspective StudiesCyclophosphamideRetrospective Studies

Substanzen

eltrombopagCyclophosphamideBenzoatesHydrazinesPyrazoles

Autor:innen und Institutionen

  • Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Translational Hematology and Oncology Research, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
  • Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Hematopoietic Stem Cell Transplantation and Cellular Therapy Program, Division of Hematology/Oncology, Department of Medicine, University of California, Irvine, California, USA.

ORCID-Profile: Qaiser Bashir, Issa Khouri, Yago Nieto, Amanda Olson, Muzaffar H Qazilbash, Rohtesh Mehta, Stefan Ciurea, Uday R Popat

Förderung

  • NCI NIH HHS
  • GlaxoSmithKline
  • Novartis
  • National Cancer Institute

Zitieren

APA

Ahmed, S., Bashir, Q., Bassett, R. L., Ullah, F., Aung, F., Valdez, B. C., Alousi, A. M., Hosing, C., Kebriaei, P., Khouri, I., Marin, D., Nieto, Y., Olson, A., Oran, B., Qazilbash, M. H., Rezvani, K., Mehta, R., Shpall, E. J., Ciurea, S., …, & Popat, U. R. (2024). Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study. American Journal of Hematology. https://doi.org/10.1002/ajh.27233

Vancouver

Ahmed S, Bashir Q, Bassett RL, Ullah F, Aung F, Valdez BC, et al. Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study. American Journal of Hematology. 2024. doi:10.1002/ajh.27233

BibTeX
@article{Ahmed2024,
  author = {Ahmed, Sairah and Bashir, Qaiser and Bassett, Roland L and Ullah, Fauzia and Aung, Fleur and Valdez, Benigno C and Alousi, Amin M and Hosing, Chitra and Kebriaei, Partow and Khouri, Issa and Marin, David and Nieto, Yago and Olson, Amanda and Oran, Betul and Qazilbash, Muzaffar H and Rezvani, Katayoun and Mehta, Rohtesh and Shpall, Elizabeth J and Ciurea, Stefan and Andersson, Borje S and Champlin, Richard E and Popat, Uday R},
  title = {Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study},
  journal = {American Journal of Hematology},
  year = {2024},
  doi = {10.1002/ajh.27233}
}
Kostenlos starten →